**Pediatric Grand Rounds – Tulsa SCM**

**Course No. 22D30**

**Tuesday, January 25, 2022**

**8:00 AM - 9:00 AM**

**\* \* \* Zoom Teleconference Meeting \* \* \***

“Puberty update for pediatricians”

- - - - - - - - - - - - - - - - - - - -

Presented by: Shelly B. Mercer, MD

Assistant Professor, OU Department of Pediatrics

Pediatric Diabetes & Endocrinology (Board Certified)

Practice Gap

* Early identification of pubertal disorders is essential to maximize the full growth and developmental potential of the child.  This lecture is designed to aid the pediatrician in early diagnosis and intervention of pubertal disorders.

Learning Objectives

* Review pubertal milestones and growth patterns
* Formulate a differential diagnosis for delayed and precocious puberty
* Outline a basic work up for patients with delayed and precocious puberty

**Nondiscrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides. Inquiries regarding non-discrimination policies may be directed to: Shaniqua Crawford, JD, Institutional Equity Officer and Title IX Coordinator, 405-325-3546, scrawford@ou.edu, or visit www.ou.edu/eoo.html.

**Accommodation Statement:** For accommodations, please contact (Name) at (phone number and/or email).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  | | | **Nature of Financial Relationship** | | |
| --- | --- | --- | --- | --- | --- |
| **Role** | **First Name** | **Last Name** | **Ineligible Company** | **What was received?** | **For what role?** |
| Planning Member | Michelle K. | Escala, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
| Course Contact | Sheryl K. | Hayes | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
| Planning Member | Keith D. | Mather, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
| Presenter | Shelly | Mercer, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |